WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Cagrilintide

Governed registry record

41 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

  1. 1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys

    DOI: 10.2337/db26-1713-p

    Source identity and connection checked by Codex (AI).

  2. 1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity

    DOI: 10.2337/db25-1969-lb

    Source identity and connection checked by Codex (AI).

  3. 2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice

    DOI: 10.2337/db26-2458-p

    Source identity and connection checked by Codex (AI).

  4. 26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS

    DOI: 10.1016/j.jacc.2026.02.688

    Source identity and connection checked by Codex (AI).

  5. 26-A-9711-ACC CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS

    DOI: 10.1016/j.jacc.2026.02.652

    Source identity and connection checked by Codex (AI).

  6. A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide’s Effects on Energy Balance

    DOI: 10.1101/2025.01.13.632726

    Source identity and connection checked by Codex (AI).

  7. A combined Cryo_EM structure of Cagrilintide-AMY1R-Gs complex

    DOI: 10.2210/pdb9uwq/pdb

    Source identity and connection checked by Codex (AI).

  8. A combined cryo_EM structure of Cagrilintide-CTR-Gs complex

    DOI: 10.2210/pdb9uwm/pdb

    Source identity and connection checked by Codex (AI).

  9. Author response for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

    DOI: 10.1111/dom.70667/v2/response1

    Source identity and connection checked by Codex (AI).

  10. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.

    DOI: 10.1002/edm2.70248PMID: 42207966

    Source identity and connection checked by Codex (AI).

  11. Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

    DOI: 10.1111/dom.70667/v1/decision1

    Source identity and connection checked by Codex (AI).

  12. Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

    DOI: 10.1111/dom.70667/v2/decision1

    Source identity and connection checked by Codex (AI).

  13. Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

    DOI: 10.1111/dom.70667/v2/review1

    Source identity and connection checked by Codex (AI).

  14. Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

    DOI: 10.1111/dom.70667/v1/review3

    Source identity and connection checked by Codex (AI).

  15. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.

    DOI: 10.1038/s41401-025-01635-2PMID: 40847076

    Source identity and connection checked by Codex (AI).

  16. A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.

    2026

    DOI: 10.1038/s42255-026-01539-3PMID: 42260119

  17. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

    2026

    DOI: 10.1097/ms9.0000000000005353PMID: 42583410

  18. Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

    2026

    DOI: 10.1007/s40200-026-01942-3PMID: 42180166

  19. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

    2026

    DOI: 10.1038/s42255-026-01603-yPMID: 42744908

  20. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

    2026

    DOI: 10.1016/s0140-6736(26)01022-6PMID: 42251856

  21. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

    2026

    DOI: 10.1016/s2213-8587(26)00125-7PMID: 42251859

  22. Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.

    2026

    DOI: 10.1016/s2213-8587(26)00129-4PMID: 42251858

  23. Cellular loci for cagrilintide action identified.

    2026

    DOI: 10.1038/s42255-026-01541-9PMID: 42260118

  24. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

    2026

    DOI: 10.1111/dom.70667PMID: 41834765

  25. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.

    2026

    DOI: 10.1016/s2213-8587(25)00402-4PMID: 42009015

  26. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

    2026

    DOI: 10.1016/s2213-8587(26)00126-9PMID: 42251860

  27. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.

    2026

    DOI: 10.1007/s40262-026-01654-0PMID: 42228334

  28. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

    2025

    DOI: 10.1056/NEJMoa2502082PMID: 40544432

  29. Cagrilintide-Semaglutide in Adults with Overweight or Obesity.

    2025

    DOI: 10.1056/nejmc2513141PMID: 41259764

  30. Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.

    2025

    DOI: 10.1016/j.lfs.2025.123845PMID: 40628316

  31. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

    2025

    DOI: 10.1056/NEJMoa2502081PMID: 40544433

  32. In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.

    2025

    DOI: 10.7326/annals-25-03745-jcPMID: 41052437

  33. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.

    2024

    DOI: 10.1111/dom.15951PMID: 39279639

  34. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.

    2024

    DOI: 10.1097/CRD.0000000000000513PMID: 36883831

  35. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

    2024

    DOI: 10.4103/ijem.ijem_45_24PMID: 39676787

  36. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

    2023

    DOI: 10.1016/s0140-6736(23)01163-7PMID: 37364590

  37. Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.

    2022

    DOI: 10.1016/j.biopha.2022.113842PMID: 36242844

  38. Cagrilintide plus semaglutide for obesity management.

    2021

    DOI: 10.1016/s0140-6736(21)00944-2PMID: 33894837

  39. Development of Cagrilintide, a Long-Acting Amylin Analogue.

    2021

    DOI: 10.1021/acs.jmedchem.1c00565PMID: 34288673

  40. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

    2021

    DOI: 10.1016/s0140-6736(21)01751-7PMID: 34798060

  41. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

    2021

    DOI: 10.1016/s0140-6736(21)00845-xPMID: 33894838